Introduction: HSP90 molecular chaperones (i.e., HSP90α, HSP90β, GRP94 and TRAP1) are potential therapeutic targets to design novel anticancer agents. However, despite numerous designed HSP90 inhibitors, most of them have failed due to unfavorable toxicity profiles and lack of specificity toward different HSP90 paralogs. Indeed, a major limitation in this field is the high structural homology between different HSP90 chaperones, which significantly limits our capacity to design paralog-specific inhibitors. Area covered: This review examines the relevance of TRAP1 in tumor development and progression, with an emphasis on its oncogenic/oncosuppressive role in specific human malignancies and its multifaceted and context-dependent functions in cancer cells. Herein, we discuss the rationale for considering TRAP1 as a potential molecular target and the strategies used to date, to achieve its compartmentalized inhibition directly in mitochondria. Expert opinion: TRAP1 targeting may represent a promising strategy for cancer therapy, based on the increasing and compelling evidence supporting TRAP1 involvement in human carcinogenesis. However, considering the complexity of TRAP1 biology, future strategies of drug discovery need to improve selectivity and specificity toward TRAP1 respect to other HSP90 paralogs. The characterization of specific human malignancies suitable for TRAP1 targeting is also mandatory.

TRAP1: a viable therapeutic target for future cancer treatments? / Lettini, Giacomo; Maddalena, Francesca; Sisinni, Lorenza; Condelli, Valentina; Matassa, Danilo Swann; Costi, Maria Paola; Simoni, Daniele; Esposito, Franca; Landriscina, Matteo. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 21:8(2017), pp. 805-815. [10.1080/14728222.2017.1349755]

TRAP1: a viable therapeutic target for future cancer treatments?

Costi, Maria Paola;
2017

Abstract

Introduction: HSP90 molecular chaperones (i.e., HSP90α, HSP90β, GRP94 and TRAP1) are potential therapeutic targets to design novel anticancer agents. However, despite numerous designed HSP90 inhibitors, most of them have failed due to unfavorable toxicity profiles and lack of specificity toward different HSP90 paralogs. Indeed, a major limitation in this field is the high structural homology between different HSP90 chaperones, which significantly limits our capacity to design paralog-specific inhibitors. Area covered: This review examines the relevance of TRAP1 in tumor development and progression, with an emphasis on its oncogenic/oncosuppressive role in specific human malignancies and its multifaceted and context-dependent functions in cancer cells. Herein, we discuss the rationale for considering TRAP1 as a potential molecular target and the strategies used to date, to achieve its compartmentalized inhibition directly in mitochondria. Expert opinion: TRAP1 targeting may represent a promising strategy for cancer therapy, based on the increasing and compelling evidence supporting TRAP1 involvement in human carcinogenesis. However, considering the complexity of TRAP1 biology, future strategies of drug discovery need to improve selectivity and specificity toward TRAP1 respect to other HSP90 paralogs. The characterization of specific human malignancies suitable for TRAP1 targeting is also mandatory.
2017
18-lug-2017
21
8
805
815
TRAP1: a viable therapeutic target for future cancer treatments? / Lettini, Giacomo; Maddalena, Francesca; Sisinni, Lorenza; Condelli, Valentina; Matassa, Danilo Swann; Costi, Maria Paola; Simoni, Daniele; Esposito, Franca; Landriscina, Matteo. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 21:8(2017), pp. 805-815. [10.1080/14728222.2017.1349755]
Lettini, Giacomo; Maddalena, Francesca; Sisinni, Lorenza; Condelli, Valentina; Matassa, Danilo Swann; Costi, Maria Paola; Simoni, Daniele; Esposito, Franca; Landriscina, Matteo
File in questo prodotto:
File Dimensione Formato  
lettini2017.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1152310
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 30
social impact